• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

PET scans in early-stage Hodgkin’s lymphoma may help guide therapy [RAPID trial]

byTomi JunandXu Gao
April 22, 2015
in Chronic Disease, Imaging and Intervention, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In patients with negative PET scans after 3 cycles of chemotherapy, 3-year progression free survival was slightly better among those who received radiotherapy than among those who received no further treatment, though prognosis was excellent in both groups.

2. Overall survival at 3 years was equivalent between the two groups.

Evidence Rating Level: 1 (Excellent)          

Study Rundown: Treatment of early-stage Hodgkin’s lymphoma traditionally involved chemotherapy combined with radiotherapy. However, the toxic effects of these treatments have led to a shift towards reduced treatment intensity where possible. The Randomised Phase III Trial to Determine the Role of FDG–PET Imaging in Clinical Stages IA/IIA Hodgkin’s Disease (RAPID) trial investigated whether positron emission tomography (PET) scanning after 3 cycles of chemotherapy could be used to guide whether further treatment was needed.

Patients with negative PET scans after 3 cycles of chemotherapy were randomized to receive either radiotherapy or no further treatment. 3-year progress-free survival was slightly higher in the group that received radiotherapy than the group that received no further treatment (94.6% vs. 90.8%, P=0.16). The pre-specified non-inferiority threshold of a 7 percentage point difference between the two groups was not met (-3.8 percentage points, 95% CI -8.8 to 1.3).

Despite this result, the trial did demonstrate that even with no further treatment, 3-year progression-free survival and overall survival were very good (90.8% and 99.0%, respectively). Furthermore, overall survival may be the more relevant outcome to consider when radiotherapy itself may cause lethal complications. Longer-term follow-up will be needed to determine whether long-term overall survival is better without radiotherapy.

Click to read the study, published today in NEJM

RELATED REPORTS

#VisualAbstract: Adolescents had an increased risk of all-cause mortality over younger children with Hodgkin lymphoma

Tau positron emission tomography is a promising prognostic device in preclinical and prodromal Alzheimer’s disease

#VisualAbstract: Topical calcineurin inhibitor use is associated with an increased risk of lymphoma

Click to read an accompanying editorial in NEJM

Relevant Reading: Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma; Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma

In-Depth [randomized controlled trial]: Four hundred and twenty patients with negative PET scans after 3 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy were randomized to receive either 30 Gy of involved-field radiotherapy or no further treatment. PET scans were interpreted at a central location.

RAPID was designed as a noninferiority trial with a noninferiority margin of 7 percentage points. The trial was designed to have 90% power to exclude a 7 percentage point difference at a 5% level of significance with 46 events. However, only 40 events were recorded, meaning that the trial was slightly underpowered.

The intention-to-treat analysis and per-protocol analyses were similar in that both demonstrated better 3-year progression-free survival with radiotherapy rather than no further treatment (intention to treat: 94.6% vs 90.8%; per-protocol: 97.1% vs. 90.8%). There were more deviations from protocol in the radiotherapy group, with 20 patients declining radiotherapy. Only 2 patients in the no further treatment group received radiotherapy.

Image: CC/Wiki/Nephron

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Hodgkin LymphomaPET
Previous Post

Gene therapy may be helpful for Wiskott-Aldrich Syndrome

Next Post

Using adhesive strips with dermal sutures does not improve cosmesis

RelatedReports

#VisualAbstract: Adolescents had an increased risk of all-cause mortality over younger children with Hodgkin lymphoma
StudyGraphics

#VisualAbstract: Adolescents had an increased risk of all-cause mortality over younger children with Hodgkin lymphoma

January 20, 2022
Childhood migraine associated with infantile colic
Chronic Disease

Tau positron emission tomography is a promising prognostic device in preclinical and prodromal Alzheimer’s disease

June 29, 2021
#VisualAbstract: Topical calcineurin inhibitor use is associated with an increased risk of lymphoma
StudyGraphics

#VisualAbstract: Topical calcineurin inhibitor use is associated with an increased risk of lymphoma

May 26, 2021
#VisualAbstract GHSG HD14: Intensified chemotherapy regimen (BEACOPP+ABVD) improved progression-free survival without improving overall survival over long-term follow-up
StudyGraphics

#VisualAbstract GHSG HD14: Intensified chemotherapy regimen (BEACOPP+ABVD) improved progression-free survival without improving overall survival over long-term follow-up

May 1, 2021
Next Post
Using adhesive strips with dermal sutures does not improve cosmesis

Using adhesive strips with dermal sutures does not improve cosmesis

Social integration may reduce suicide risk in male health professionals

Mindfulness-based cognitive therapy is not superior to maintenance antidepressants in preventing depression recurrence or relapse [PREVENT trial]

Prednisolone and pentoxifylline do not reduce mortality in alcoholic hepatitis [STOPAH trial]

Prednisolone and pentoxifylline do not reduce mortality in alcoholic hepatitis [STOPAH trial]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir
  • Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial
  • #VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.